Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine. Lian J, Zhuang X, Chen Y, Lin Q, et al. Cancer 2025;131:e70053.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lian J, Zhuang X, Chen Y, Lin Q, et al. Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine. Cancer 2025;131:e70053.
PMID: 40856205